(Q37782588)

English

Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review

scientific article published on January 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

cost-effectiveness analysis

1 reference

based on heuristic

inferred from title

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

Gabrielle van der Velde

1

object named as

Gabrielle van der Velde

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

object named as

Murray Krahn

7

0 references

Claire Bombardier

6

object named as

Claire Bombardier

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

William Witteman

5

object named as

William Witteman

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

4

object named as

Luciano Ieraci

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

Marcio Carlos Machado

3

object named as

Márcio Machado

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

author name string

Ba' Pham

2

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

publication date

1 January 2011

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

Arthritis Care and Research

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

63

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

65-78

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

The epidemiology of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

The burden of rheumatoid arthritis and access to treatment: health burden and costs

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Cardiovascular morbidity and mortality in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Employment and work disability in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the cooperative systematic studies of the rheumatic diseases program randomized clinical trial of methotrexate, auranofin, or a combination of the two.

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Systematic reviews of economic evaluations: utility or futility?

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Cost-effectiveness analysis of biological treatments for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK.

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK.

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Not all "quality-adjusted life years" are equal.

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Handling uncertainty in cost-effectiveness models

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

The costs of rheumatoid arthritis: an international long-term view

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Growth and quality of the cost-utility literature, 1976-2001.

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

The quality of reporting in published cost-utility analyses, 1976-1997.

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Are methods for estimating QALYs in cost-effectiveness analyses improving?

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Recommendations of the Panel on Cost-effectiveness in Health and Medicine

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Quality of systematic reviews of economic evaluations in health care

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Infliximab in active early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks. An open-label extension study

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Modelling the cost effectiveness of TNF- antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Biologic drugs for rheumatoid arthritis in the medicare program: A cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1002%2FACR.20338

21 January 2018

Identifiers

10.1002/ACR.20338

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37782588&oldid=2178942735"